AKT1 and acute lymphoblastic leukemia: T-ALL cells were treated with the AKT pathway inhibitor BEZ235 together with RO48-8071 at various concentrations, and MTS assays demonstrated that BEZ235 augmented the efficacy of RO48-8071 in inhibiting cell viability (Fig. 7F).